- Home
- NFE vs XFOR Comparison
NFE vs XFOR Comparison
Compare NFE & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFE | XFOR |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | 45 |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 377.3M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | NFE | XFOR |
|---|---|---|
| Price | $0.34 | $4.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.50 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 2.1M | 583.8K |
| Earning Date | 04-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,504,037,000.00 | N/A |
| Revenue This Year | $110.34 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.32 | $1.35 |
| 52 Week High | $3.38 | $4.83 |
Technical Indicators
Market Signals| Indicator | NFE | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 53.76 |
| Support Level | $0.32 | $3.58 |
| Resistance Level | $0.38 | $4.52 |
| Average True Range (ATR) | 0.02 | 0.22 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 31.44 | 72.08 |
Price Performance
Historical ComparisonAbout NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.